Начало >> Статьи >> Литература >> Рекомендации по лечению аналогами инсулина детей и подростков

Литература - Рекомендации по лечению аналогами инсулина детей и подростков

Оглавление
Рекомендации по лечению аналогами инсулина детей и подростков
Цели инсулинотерапии
Сведения об аналогах инсулина
Начало инсулинотерапии
Особенности инсулинотерапии диабета 2 типа
Выбор режима введения инсулина
Трехразовое введение инсулина
Базальная терапия с введением быстродействующего инсулина
Использование инсулиновых насосов
Особенности лечения маленьких детей
Использование аналогов инсулина для решения проблем
Переход на лечение аналогами инсулина
Мониторинг лечения
Литература

8. ЛИТЕРАТУРА

1.Chase Н, Lockspeiser Т, Реегу В et а\. The impact of the diabetes control and complications trial and Humalog insulin on glycohemoglobin levels and severe hypoglycemia in Type 1 diabetes. Diabetes Care 2001; 24(3): 430-4.

2. International Society for Pediatric and Adolescent Diabetes. ISPAD consensus guidelines for the management of Type 1 diabetes mellitus in children and adolescents. PGF Swift (ed). The Netherlands: Medforum, 2000.

3.   Kelnar C. Textbook of childhood and adolescent diabetes. London: Chapman and Hall, 1995.

4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329(14): 977-86.

5. UK prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-53.

6.  Rapaport R, Sills IN. Implications of the DCCT for children and adolescents with IDDM. N J Med 1994; 91(4): 227~8.

7.  Brink SJ. How to apply the experience from the diabetes control and complications trial to children and adolescents? Ann Med 1997; 29(5): 425-38.

8.  Danne T, Kordonouri O, Hovener G, Weber B. Diabetic angiopathy in children. Diabet Med 1997; 14(12): 1012-25.

9. Ohkubo Y, Kishikawa H, Araki E eta\. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6- year study. Diabetes Res Clin Pract 1995; 28(2): 103-17.

10.Gammeltoft S, Falck Hansen B, Dideriksen L eta\. Insulin aspart: a novel rapid-acting human insulin analogue. Exp Opin Invest Drugs 1999; 8(9): 1431-41.

11.   Mudaliar S, Lindberg F, Joyce M, eta\. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22(9): 1501-6.

12.Mortensen HB, Lindholm A, Olsen BB, Hyelleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with Type 1 diabetes. Eur J Paediatr 2000; 159(7): 483~8.

13.Raskin P, Guthrie R, Leiter L et al. Use of insulin aspart, a fast-acting insulin

type 1 diabetes. Diabetes Care 2000; 23(5):583~8.

14. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomised controlled trial. Diabet Med 2000; 17: 762-70.

15.Heller S, Colagiuri S, Vaaler S etal. Reduced hypoglycemia with insulin aspart: A double-blind, randomised, crossover trial in Type 1 diabetic patients. Diabetes 2001; 50(2): A137.

16.   Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000; 56(5): 399-403.

17.   O'Hagan M, Greene S. Pre-mixed insulin delivered by disposable pen in the management of children with diabetes. Diabet Med 1993; 10(10): 972~5.

18. Mortensen HB, Robertson KJ, Aanstoot HJ et a\. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescents in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabet Med 1998; 15(9): 752-9.

19. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20(10): 1612-4.

20.  McSorley P, Bell P, Jacobsen L eta\. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind cross-over study in people with Type 2 diabetes. Submitted to Clin Ther 2001.

21. Hermansen K, Vaaler S, Madsbad S et al. Biphasic insulin aspart 30 improves postprandial glycemic control. Diabetes 2001; 50(2): A95.

22.  Bmhrn B, Home P, Behrend С et al. Premixed insulin aspart 30 versus premixed human insulin 30/70 twice daily: A randomized 3-month comparison in Type 1 and Type 2 diabetic patients. Submitted to Diabet Med 2001.

23.  Data on file, Novo Nordisk BiAsp-1069.

24.  Kurtzhals P, Schflffer L, Suurensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49(6): 999-1005.

25.  Funnell MM, Anderson RM, Arnold MS et a\. Empowerment: An idea whose time has come in diabetes education. Diabetes Educ 1991; 17(1): 37-41.

26. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000; 23(3): 381-9.

27. Boland E, Grey M, Oesterle A et a\. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22(11): 1779-84.

28.  Maniatis AK, Klingensmith GJ, Slover RH et al. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001; 107(2): 351-6.

29. Bode В, Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with Type 1 diabetes. Diabetes Care 2001; 24(1): 69~72.

30. Bode BW, Weinstein R, Bell D et al. Insulin aspart efficacy and safety compared to buffered regular insulin (velosulin) and insulin lispro for continuous subcutaneous insulin infusion. Diabetes Care 2002, in press.

31.   The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46(2): 271-86.

32.Beregszaszi M, Tubiana Rufi N, Benali К et al. Nocturnal hypoglycemia in children and adolescents with insulin-dependent diabetes mellitus: prevalence and risk factors. J Pediatr 1997; 131(1 Pt 1): 27-33.

33. Mohn A, Matyka K, Harris D et al. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Diabetes Care 1999; 22(1): 27-32.

34. Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. Diabetes Care 2000; 23(5): 579~82.

35. Kaufman F, Halvorson M, Miller D et al. Insulin pump therapy in Type 1 pediatric patients: now and into the year 2000. Diabetes Metab Res Rev 1999; 15(5): 338-52.

36. Rami B, Schober E. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. Eur J Pediatr 1997; 156(11): 838-40.

37. Rutledge KS, Chase HP, Klingensmith GJ et al. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997; 100(6): 968~72.

38.  DanneT, Aaman J, Schober E ef al. Preprandial vs. postprandial insulin aspart treatment in Type 1 diabetic children and adolescents. Diabetologia 2001; 44(Suppl. 1): A257.

39. Travaglini MT, Garg SK, Chase HP. Use of insulin lispro in the outpatient management of ketonuria. Arch Pediatr Adolesc Med 1998; 152(7): 672-5.



 
« Рекомендации по ведению пациентов с инфарктом миокарда с подъемом сегмента ST   Респираторные заболевания у детей »